Locating the Future of ESG: The Promise of Geospatial Data in Advancing ESG Research

Autor: Ulrich Atz, Christopher C. Bruno

Publikováno v: Sustainability and Climate Change. 16:2-9

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d6e9bc75bae0134455657acf19189dff
https://doi.org/10.1089/scc.2022.0110

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial.

Autor: Platt HL; Merck & Co, Inc, Rahway, NJ, USA. Electronic address: heather.platt@merck.com., Bruno C; Merck & Co, Inc, Rahway, NJ, USA., Buntinx E; Anima Research Center, Alken, Belgium., Pelayo E; Amri, Miami, FL, USA., Garcia-Huidobro D; Pontificia Universidad Católica de Chile, Santiago, Chile., Barranco-Santana EA; Ponce Health Sciences University, Ponce, Puerto Rico., Sjoberg F; Karolinska University Hospital, Stockholm, Sweden., Song JY; Korea University College of Medicine, Seoul, South Korea., Grijalva CG; Vanderbilt University Medical Center, Nashville, TN, USA., Orenstein WA; Emory University, Atlanta, GA, USA., Morgan L; Merck & Co, Inc, Rahway, NJ, USA., Fernsler D; Merck & Co, Inc, Rahway, NJ, USA., Xu W; Merck & Co, Inc, Rahway, NJ, USA., Waleed M; Merck & Co, Inc, Rahway, NJ, USA., Li J; Merck & Co, Inc, Rahway, NJ, USA., Buchwald UK; Merck & Co, Inc, Rahway, NJ, USA.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Oct; Vol. 24 (10), pp. 1141-1150. Date of Electronic Publication: 2024 Jul 01.

Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).

Autor: Johnson MG; Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: matthew.johnson1@merck.com., Bruno C; Merck & Co., Inc., Kenilworth, NJ, USA., Castanheira M; JMI Laboratories, North Liberty, IA, USA., Yu B; Merck & Co., Inc., Kenilworth, NJ, USA., Huntington JA; Merck & Co., Inc., Kenilworth, NJ, USA., Carmelitano P; Merck & Co., Inc., Kenilworth, NJ, USA., Rhee EG; Merck & Co., Inc., Kenilworth, NJ, USA., De Anda C; Merck & Co., Inc., Kenilworth, NJ, USA., Motyl M; Merck & Co., Inc., Kenilworth, NJ, USA.

Publikováno v: International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Mar; Vol. 57 (3), pp. 106278. Date of Electronic Publication: 2021 Jan 09.

Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP).

Autor: Huntington JA; Merck & Co., Inc., Kenilworth, New Jersey, USA., Yu B; Merck & Co., Inc., Kenilworth, New Jersey, USA Brian.Yu@merck.com., Li L; Merck & Co., Inc., Kenilworth, New Jersey, USA., Jensen E; Merck & Co., Inc., Kenilworth, New Jersey, USA., Bruno C; Merck & Co., Inc., Kenilworth, New Jersey, USA., Boakye M; Merck & Co., Inc., Kenilworth, New Jersey, USA., Zhang Z; Merck & Co., Inc., Kenilworth, New Jersey, USA., Gao W; Merck & Co., Inc., Kenilworth, New Jersey, USA., Feng HP; Merck & Co., Inc., Kenilworth, New Jersey, USA., Rhee E; Merck & Co., Inc., Kenilworth, New Jersey, USA.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2020 Nov 17; Vol. 64 (12). Date of Electronic Publication: 2020 Nov 17 (Print Publication: 2020).